Sulvodutide is the first glucagon/GLP-1 receptor dual agonist to demonstrate high efficacy in treating liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.
Surbodutide shows remarkable improvement in patients with liver fibrosis associated with metabolic dysfunction-associated steatohepatitis
Leave a comment
